Framework Proposed to Pair New Tuberculosis Drugs With Resistance Diagnostics

This perspective argues that development of new tuberculosis drugs and their companion resistance tests should proceed concurrently, a stewardship-relevant proposal rather than a clinical trial.

tuberculosisbedaquilinepretomanidlinezolidBPaLdrug resistancedrug-susceptibility testingcompanion diagnosticsantimicrobial stewardshipperspective article Infectious Disease / Antimicrobials

Background Information

Rising resistance threatens tuberculosis treatment efficacy.

Resistance to new tuberculosis drugs is growing, threatening treatment efficacy. The article outlines a framework for integrating drug susceptibility testing with drug development to combat resistance. The framework emphasizes collaboration to ensure resistance detection aligns with new drug introductions, which is crucial for clinical decision-making. Align tuberculosis drug development with resistance testing to preserve treatment efficacy.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Saluzzo F, Yerlikaya S, Dorman SE, Eisenach K, Farhat MR, Ismail N, Lienhardt C, Walker TM, Jones F, Yepes A, Penn-Nicholson A, Ruhwald M, Kana B, Denkinger CM, Cirillo DM

Citation: Saluzzo F, Yerlikaya S, Dorman SE, et al. Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development. The Lancet. Infectious diseases. 2026;26(6):e248-e256. doi:10.1016/S1473-3099(25)00547-X

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →